Serum pro-matrix metalloproteinase-3 as an indicator of disease activity and severity in rheumatoid arthritis: Comparison with traditional markers

Rheumatology International

Volumn 27, Issue 8, 2007, Pages 715-722

  Ateş, Aşkin ^a,b   Türkçapar, Nuran ^a   Ölmez, Ümit ^a   Tiryaki, Olcay ^a   Düzgün, Nurşen ^a   Uǧuz, Emre ^a   Duman, Murat ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

C reactive protein; Disease activity; Erythrocyte sedimentation rate; Joint damage; Rheumatoid arthritis; Serum pro matrix metalloproteinase 3

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INDICATOR; STROMELYSIN;

ARTICLE; CLINICAL EXAMINATION; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JOINT SWELLING; LABORATORY TEST; MAJOR CLINICAL STUDY; MORNING STIFFNESS; PRIORITY JOURNAL; PROXIMAL INTERPHALANGEAL JOINT; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ADULT; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 34248198505     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-007-0338-1     Document Type: Article

References (35)

1. Okada Y (2001) Proteinases and matrix degradation. In: Ruddy S, Harris ED, Sledge CB, Budd RC, Sergent JS (eds) Kelly's textbook of rheumatology. W.B. Saunders, Philadelphia, pp 55-72
2. Hasty KA, Reife RA, Kang AH, Stuart JM (1990) The role of stromelysin in the cartilage destruction that accompanies inflammatory arthritis. Arthritis Rheum 33:388-397
3. Nagase H (1997) Activation mechanisms of matrix metalloproteinases. Biol Chem 378:151-160
4. Manicourt DH, Fujimoto N, Obata K, Thonar EJMA (1995) Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation. Arthritis Rheum 38:1031-1039
5. Taylor DJ, Cheung NT, Dawes PT (1994) Increased serum pro-MMP-3 in inflammatory arthritides: a potential indicator of synovial inflammatory monokine activity. Ann Rheum Dis 53:768-772
6. Yoshihara Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, Shimmei M (1995) Increased levels of stromelysin-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 38:969-975
7. Keyszer G, Lambiri I, Nagel R, Keysser C, Keysser M, Gromnica-Ihle E, Franz J, Burmester GR, Jung K (1999) Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol 26:251-258
8. Ichikawa Y, Yamada C, Horiki T, Hoshina Y, Uchiyama M (1998) Serum matrix metalloproteinase-3 and fibrin degradation products levels correlate with clinical disease activity in rheumatoid arthritis. Clin Exp Rheumatol 16:533-540
9. Posthumus MD, Limburg PC, Westra J, van Leeuwen MA, van Rijswijk MH (1999) Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis. Rheumatology 38:1081-1087
10. Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, Kamatani N (2000) Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 43:852-858
11. Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, Houssiau FA, Malaise MG (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161-166
12. Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik B, Skowronski J, Chwiecko J (2002) Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis. Rheumatology 41:78-87
13. Sasaki S, Iwata H, Ishiguro N, Obata K, Miura T (1994) Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 13:228-233
14. Ribbens C, Andre B, Kaye O, Kaiser MJ, Bonnet V, Jaspar JM, de Groote D, Franchimont N, Malaise MG (2000) Synovial fluid matrix metalloproteinase-3 levels are increased inflammatory arthritides whether erosive or not. Rheumatology 39:1357-1365
15. Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T, Fujikawa K, Okada Y (2000) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 59:455-461
16. Gravallese EM, Darling JM, Ladd AL, Katz JN, Glimcher LH (1991) In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium. Arthritis Rheum 34:1076-1084
17. Ishiguro N, Ito T, Obata K, Fujimoto N, Iwata H (1996) Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis. J Rheumatol 23:1599-1604
18. Ribbens C, Andre B, Jaspar JM, Kaye O, Kaiser MJ, de Groote D, Malaise MG (2000) Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol 27:888-893
19. Wollheim FA, Eberhardt KB (1992) The search for laboratory measures of outcome in rheumatoid arthritis. Baillieres Clin Rheumatol 6:69-73
20. van Leeuwen MA, van der Heijde DM, van Rijswijk MH, Houtman PM, van Riel PL, van de Putte LB, Limburg PC (1994) Inter-relationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol 21:425-429
21. So A, Chamot AM, Peclat V, Gerster JC (1999) Serum MMP-3 in rheumatoid arthritis: correlation with systemic inflammation but not with erosive status. Rheumatology (Oxford) 38:407-410
22. Posthumus MD, Limburg PC, Westra J, van Leeuwen MA, van Rijswijk MH (2000) Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression. J Rheumatol 27:2761-2768
23. Cheung NT, Dawes PT, Poulton KV, Ollier WER, Taylor DJ, Mattey DL (2000) High serum levels of pro-matrix metalloproteinase-3 are associated with greater radiographic damage and the presence of the shared epitope in patients with rheumatoid arthritis. J Rheumatol 27:882-887
24. Cunnane G, Fitzgerald O, Beeton C, Cawston TE, Bresnihan B (2001) Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis Rheum 44:2263-2274
25. Posthumus MD, Limburg PC, Westra J, van Leeuwen MA, van Rijswijk MH (2003) Serum matrix metalloproteinase 3 levels in comparison to C-reactive protein in periods with and without progression of radiological damage in patients with early rheumatoid arthritis. Clin Exp Rheumatol 21:465-472
26. Tchetverikov I, Lard LR, DeGroot J, Verzijl N, TeKoppele JM, Breedveld FC, Huizinga TW, Hanemaaijer R (2003) Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 62:1094-1099
27. Jensen T, Klarlund M, Hansen M, Jensen KE, Skjodt H, Hyldstrup L; Danisit TIRA Group (2004) Connective tissue metabolism in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity, bone mineral density, and radiographic outcome. J Rheumatol 31:1698-1708
28. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
29. Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137-145
30. Larsen A, Dale K, Eek M (1977) Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 8:481-491
31. Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P, Buchanan WW (1968) Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 37:393-406
32. Prevoo MLL, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44-48
33. Paulus HE, Ramos B, Wong WK, Ahmed A, Bulpitt K, Park G, Sterz M, Clements P (1999) Equivalence of the acute phase reactants C-reactive protein, plasma viscosity, and Westergren erythrocyte sedimentation rate when used to calculate American college of rheumatology 20% improvement criteria or the disease activity score in patients with early rheumatoid arthritis. J Rheumatol 26:2324-2331
34. Garnero P, Rousseau JC, Delmas PD (2000) Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum 43:953-968
35. Mudgett JS, Hutchinson NI, Chartrain NA, Forsyth AJ, McDonnell J, Singer II, Bayne EK, Flanagan J, Kawka D, Shen CF, Stevens K, Chen H, Trumbauer M, Visco DM (1998) Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum 41:110-121